- Home
- UGRO vs XBIO Comparison
UGRO vs XBIO Comparison
Compare UGRO & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- XBIO
- Stock Information
- Founded
- UGRO 2014
- XBIO N/A
- Country
- UGRO United States
- XBIO United States
- Employees
- UGRO N/A
- XBIO N/A
- Industry
- UGRO Industrial Specialties
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- XBIO Health Care
- Exchange
- UGRO Nasdaq
- XBIO Nasdaq
- Market Cap
- UGRO 3.8M
- XBIO 4.4M
- IPO Year
- UGRO N/A
- XBIO N/A
- Fundamental
- Price
- UGRO $0.58
- XBIO $3.60
- Analyst Decision
- UGRO Strong Buy
- XBIO Hold
- Analyst Count
- UGRO 1
- XBIO 1
- Target Price
- UGRO $3.00
- XBIO N/A
- AVG Volume (30 Days)
- UGRO 14.7M
- XBIO 14.2K
- Earning Date
- UGRO 10-30-2025
- XBIO 11-11-2025
- Dividend Yield
- UGRO N/A
- XBIO N/A
- EPS Growth
- UGRO N/A
- XBIO N/A
- EPS
- UGRO N/A
- XBIO N/A
- Revenue
- UGRO $59,985,138.00
- XBIO $2,446,221.00
- Revenue This Year
- UGRO N/A
- XBIO $1.99
- Revenue Next Year
- UGRO $31.25
- XBIO $20.00
- P/E Ratio
- UGRO N/A
- XBIO N/A
- Revenue Growth
- UGRO N/A
- XBIO N/A
- 52 Week Low
- UGRO $0.26
- XBIO $2.20
- 52 Week High
- UGRO $1.92
- XBIO $5.27
- Technical
- Relative Strength Index (RSI)
- UGRO 61.24
- XBIO 68.47
- Support Level
- UGRO $0.44
- XBIO $2.97
- Resistance Level
- UGRO $0.67
- XBIO $3.15
- Average True Range (ATR)
- UGRO 0.08
- XBIO 0.21
- MACD
- UGRO 0.02
- XBIO 0.07
- Stochastic Oscillator
- UGRO 49.51
- XBIO 89.13
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.